Global Health Dialogues: BioPerfectus Hosts Gates Foundation Delegation


Taizhou, Jiangsu, China, December 1, 2023 — BioPerfectus was honored to host a distinguished delegation, including representatives from the Bill & Melinda Gates Foundation (referred to as the Gates Foundation), PATH, Global Health Labs (GHLabs), and the Clinton Health Access Initiative (CHAI). The guests were warmly welcomed by Dr. Wang Guoqiang, Chairman and CEO of BioPerfectus, alongside Dr. Liu Zhonghua, Executive Vice President, Dr. Joseph Chow, Vice President, and Dr. Jin Wei, General Manager of the Research and Development Center.

Established in 2000, the Gates Foundation, led by Bill and Melinda Gates, stands as one of the world's largest private charitable foundations, dedicated to proactive global health initiatives. BioPerfectus, a leading global supplier in molecular diagnostics, has become a crucial destination for the Gates Foundation.


During the visit, both parties discussed expanding the impact of innovative achievements, with a focus on addressing challenges in low- and middle-income countries. Topics included critical areas like infectious disease diagnosis and prevention, as well as women and children's health. Dr. Joseph Chow detailed BioPerfectus' research plans in HPV, STD, and tuberculosis, as well as exploration in the POCT and home diagnostics market. He looks forward to deepening collaboration with the Gates Foundation, PATH, and CHAI, actively integrating resources for joint health innovation outcomes.

The dialogue between BioPerfectus and the Gates Foundation underscores a mutual commitment to advancing global health initiatives. At BioPerfectus, our unwavering dedication remains, propelling us to contribute meaningfully to the betterment of global health standards.


About BioPerfectus

BioPerfectus (SSE: 688399) stands at the forefront of the molecular diagnostics industry, with a specialization in "diagnostics for infectious diseases and women's and children's health". Founded in 2010, BioPerfectus consistently emphasizes R&D, manufacturing, and the distribution of in-vitro diagnostic reagents and instruments. Through strategic planning, the company has seamlessly integrated its efforts from the development and production of upstream core materials to downstream diagnostic services. With a diverse portfolio of over 600 products, BioPerfectus caters to a broad spectrum of medical institutions, CDCs, and independent clinical laboratories across more than 100 countries and regions. Further solidifying its position in molecular diagnostics, BioPerfectus proactively ventures into high-growth areas such as POCT (Point-of-Care Testing). The company's strategic focus is on expanding applications, refining its product range, and making inroads into international markets. Guided by the vision "To be one of the top global IVD suppliers," and driven by the mission of "For a healthier future," BioPerfectus utilizes precise, effective, and streamlined diagnostic techniques with the aim of pioneering advanced early screening and diagnostic methods for infectious diseases and major health challenges, thereby enhancing the quality of life and championing global health.